Nonclinical precedent Request an invite

Tegsedi: what safety margin did regulators accept?

inotersen · TTR (ASO)
Safety margin at NOAEL
AUC margins at NOAELs for monkey thrombocytopenia and rat kidney toxicity ≤ ~2-fold
“Safety margins based on AUCs at the no observed adverse effect levels (NOAELs) for severe thrombocytopenia in monkeys and kidney toxicity in rats were ≤ ~2-fold.”
✓ VerifiedFDA pharmacology/toxicology review, p. 15Source ↗
NOAEL / key findings
Monkey 39-wk NOAEL 6 mg/kg/wk (severe thrombocytopenia); rat NOAEL 5 mg/kg (glomerulopathy); margins <=~2-fold
“The NOAEL was 6 mg/kg/week, based on the severe thrombocytopenia observed at 10 and 20 mg/kg/week.”
✓ VerifiedFDA pharmacology/toxicology review, p. 70Source ↗

Same question, other oligonucleotides

Amondys 45

casimersen · DMD exon 45 (PMO)
Juvenile rat no-effect dose (300 mg/kg) ~4x human AUC at 30 mg/kg/week

Amvuttra

vutrisiran · TTR (siRNA)
NOAELs (150 mg/kg rat, 300 mg/kg monkey monthly) ~600x and ~4400x human AUC at 25 mg Q3M

Dawnzera

donidalorsen · Prekallikrein / KLKB1 (ASO)
Monkey NOAEL 6 mg/kg/wk: ~29x (monthly) and ~58x (Q8W) clinical exposure

Exondys 51

eteplirsen · DMD exon 51 (PMO)
Low: NOAEL exposure 3.4x human in monkey and <1x in mdx mouse (surrogate); highest doses 17-20x

Givlaari

givosiran · ALAS1 (siRNA)
No adverse findings at 3.5-fold (rat) and 26.3-fold (monkey) the exposure at the maximum recommended human dose

Heplisav-B

hepatitis B vaccine (recombinant), adjuvanted · TLR9 (CpG 1018 adjuvant)
Monkey NOAEL 0.5 mg/kg CpG adjuvant, >10-fold the clinical mg/kg dose, for systemic immunostimulation

Izervay

avacincaptad pegol · C5 (aptamer)
Dog intravitreal NOAEL 1.0 mg/eye = 0.66x the recommended clinical dose

Kynamro

mipomersen · APOB (ASO)
Monkey chronic (12-month) NOAEL 10 mg/kg/week approximates clinical exposure at 200 mg/wk (body surface area)

Leqvio

inclisiran · PCSK9 (siRNA)
NOAEL ~48.9x (rat) and ~99.6x (monkey) human AUC at 300 mg; 99x/101x by Cmax

Macugen

pegaptanib · VEGF-165 (aptamer)
Rat IV NOAEL plasma concentration ~240x human Cmax at 3 mg/eye

Oxlumo

lumasiran · HAO1 (siRNA)
Rat NOAEL 200 mg/kg ~44x and monkey NOAEL 300 mg/kg ~150x human AUC

Qalsody

tofersen · SOD1 (ASO)
Monkey 9-month IT NOAEL 12 mg (HED 120 mg) ~1.2x the 100 mg human dose by CSF-volume scaling

Qfitlia

fitusiran · Antithrombin / SERPINC1 (siRNA)
Monkey 39-week top dose 0.5 mg/kg/week (tolerated) is below the MRHD on a BSA dose basis

Redemplo

plozasiran · APOC3 (siRNA)
Monkey NOAEL 180 mg/kg Q4W (highest dose): 140-fold MRHD by BSA

Rivfloza

nedosiran · LDHA (siRNA)
Juvenile monkey NOAEL 100 mg/kg: AUC ~29-fold human exposure

Rytelo

imetelstat · Telomerase (oligo)
Mouse NOAEL 2.4x and monkey HNSTD 28.1x human exposure at recommended dose

Spinraza

nusinersen · SMN2 (ASO)
No margin: monkey 53-week neurotoxicity no-effect dose 0.3 mg gave CSF 12 ng/mL, within patient levels (7-35 ng/mL)

Tryngolza

olezarsen · APOC3 (ASO)
Monkey NOAEL 6 mg/kg/wk ~6x MRHD (80 mg/month) by BSA

Vyondys 53

golodirsen · DMD exon 53 (PMO)
Juvenile rat NOAEL 100 mg/kg ~2.6x human plasma exposure at 30 mg/kg

Wainua

eplontersen · TTR (ASO)
Monkey NOAEL 134x human AUC (112x Cmax) at 45 mg

Zanvastro

zilganersen · GFAP (ASO)
Monkey NOAEL 5x, mouse 17x the proposed 50 mg dose (CSF-volume-normalized dose)

Cyfendus

anthrax vaccine adsorbed, adjuvanted · TLR9 (CpG 7909 adjuvant)
Not stated in public reviews

Defitelio

defibrotide · Fragmented DNA oligonucleotides
Not stated in public reviews

Onpattro

patisiran · TTR (siRNA)
Not stated in public reviews

Viltepso

viltolarsen · DMD exon 53 (PMO)
Not stated in public reviews

Vitravene

fomivirsen · CMV IE2 mRNA (ASO)
Not stated in public reviews

Waylivra

volanesorsen · APOC3 (ASO)
Not stated in public reviews

Summary across all 28 oligonucleotides →